Contrary to the proposed primary role for innate immune cells in the anticancer activities of CD47-targeted therapeutics, several independent groups have found CD8 T cells to be essential for therapeutic responses to CD47 blockade in immune-competent mouse tumor models including for cutaneous melanoma [10,63,64,65]. This evidence concerns the gene CD47 and neoplasm.